This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor::
—I wish to comment on the review of a book on bacitracin, published on page 424 in the September, 1952, issue of the Archives of Internal Medicine.I have no personal interest in the publishers of the book, nor in bacitracin, with the exception that I did a good deal of work with this antibiotic. I do not believe that the reviewer's implication that bacitracin is made to be the drug of choice in the treatment of amebiasis by the book is justified on the basis of what is said in the book.I believe that if the reviewer refers to the papers published on the therapy of amebiasis with bacitracin, he will find it stated that cure rates following use of this drug are approximately 65% and that the drug is apparently quite active in some instances in terminating episodes of acute ulcerative amebic colitis. Obviously,
Most H. BACITRACIN. AMA Arch Intern Med. 1953;91(3):414. doi:10.1001/archinte.1953.00240150133014
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.